Similar articles

• Recent developments in the management of emesis with the 5-HT3 antagonist granisetron.

  Button D. Button D. Semin Oncol Nurs. 1990 Nov;6(4 Suppl 1):14-9. doi: 10.1016/0749-2081(90)90041-3. Semin Oncol Nurs. 1990. PMID: 2177568 Review. No abstract available.
• Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary.

  Pintens H. Pintens H. Cancer Treat Rev. 1990 Sep;17(2-3):307-10. doi: 10.1016/0305-7372(90)90062-k. Cancer Treat Rev. 1990. PMID: 2176932 Review. No abstract available.
• Caring for the cancer patient: managing emesis now. An interactive workshop. Proceedings of a satellite symposium to the 6th European Conference on Clinical Oncology. Florence, October 1991.

  [No authors listed] [No authors listed] Eur J Cancer. 1992;28A Suppl 1:S1-44. Eur J Cancer. 1992. PMID: 1352697 No abstract available.
• The symptomatic control of cytostatic drug-induced emesis. A recent history and review.

  Joss RA, Brand BC, Buser KS, Cerny T. Joss RA, et al. Eur J Cancer. 1990;26 Suppl 1:S2-8. Eur J Cancer. 1990. PMID: 2169781
• Are granisetron and ondansetron equivalent in the clinic?

  Dilly S. Dilly S. Eur J Cancer. 1992;28A Suppl 1:S32-5. doi: 10.1016/0959-8049(92)90634-e. Eur J Cancer. 1992. PMID: 1320918 Review.